137 related articles for article (PubMed ID: 37199427)
21. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
24. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
25. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
26. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Mills A; Arribas JR; Andrade-Villanueva J; DiPerri G; Van Lunzen J; Koenig E; Elion R; Cavassini M; Madruga JV; Brunetta J; Shamblaw D; DeJesus E; Orkin C; Wohl DA; Brar I; Stephens JL; Girard PM; Huhn G; Plummer A; Liu YP; Cheng AK; McCallister S;
Lancet Infect Dis; 2016 Jan; 16(1):43-52. PubMed ID: 26538525
[TBL] [Abstract][Full Text] [Related]
27. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
[TBL] [Abstract][Full Text] [Related]
30. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
31. Changes in Bone Mineral Density During and After Lactation in Ugandan Women With HIV on Tenofovir-Based Antiretroviral Therapy.
Nabwire F; Prentice A; Hamill MM; Fowler MG; Byamugisha J; Kekitiinwa A; Goldberg GR
J Bone Miner Res; 2020 Nov; 35(11):2091-2102. PubMed ID: 32573842
[TBL] [Abstract][Full Text] [Related]
32. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
[TBL] [Abstract][Full Text] [Related]
34. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
35. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
[TBL] [Abstract][Full Text] [Related]
36. Interventions for preventing late postnatal mother-to-child transmission of HIV.
Horvath T; Madi BC; Iuppa IM; Kennedy GE; Rutherford G; Read JS
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD006734. PubMed ID: 19160297
[TBL] [Abstract][Full Text] [Related]
37. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
Kalemeera F; Godman B; Stergachis A; Rennie T
Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
[No Abstract] [Full Text] [Related]
38. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
[TBL] [Abstract][Full Text] [Related]
39. Analysis of bone mineral content in horizontally HIV-infected children naïve to antiretroviral treatment.
Mora S; Zamproni I; Giacomet V; Cafarelli L; Figini C; Viganò A
Calcif Tissue Int; 2005 May; 76(5):336-40. PubMed ID: 16075365
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.
Ramalho J; Martins CSW; Galvão J; Furukawa LN; Domingues WV; Oliveira IB; Dos Reis LM; Pereira RM; Nickolas TL; Yin MT; Eira M; Jorgetti V; Moyses RM
J Bone Miner Res; 2019 Sep; 34(9):1574-1584. PubMed ID: 31269294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]